Cognition Therapeutics Aligns With FDA on Zervimesine Phase 3 Trial

Cognition Therapeutics announced on October 22, 2026, that it has aligned with the U.S. Food and Drug Administration (FDA) on key elements of a planned registrational Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies (DLB). The agreement covers patient selection, dose, treatment duration and clinical endpoints, allowing the company to advance protocol finalisation.

The planned study will enrol patients with mild-to-moderate DLB and randomise them to receive either 100 mg of oral zervimesine once daily or placebo for nine months. The company said its discussions involved the FDA’s Divisions of Neurology and Psychiatry within the Office of Neuroscience.

The development marks a regulatory milestone for Cognition, but it does not establish zervimesine’s efficacy or guarantee approval. The pivotal trial will need to demonstrate that treatment provides clinically meaningful benefits with an acceptable safety profile.

Hallucinations and Delusions to Anchor the Primary Endpoint

The planned Phase 3 trial will use the Neuropsychiatric Inventory hallucinations and delusions subscale (NPI-2) as its primary endpoint. The Alzheimer’s Disease Cooperative Study–Activities of Daily Living (ADCS-ADL) scale will serve as a key secondary endpoint to assess treatment effects on daily functioning.

These measures reflect the clinical burden of DLB, which can affect cognition, movement and behaviour. Hallucinations and delusions are particularly important because they can emerge early, worsen as the disease progresses and create substantial challenges for patients and caregivers.

Cognition’s Chief Medical Officer, Anthony O. Caggiano, said that blood-based biomarkers are not currently available to measure DLB progression and that clinicians therefore rely on observable clinical features. The company believes changes in psychosis symptoms could provide an indication of underlying disease progression.

However, changes in hallucinations and delusions should not automatically be interpreted as evidence of disease modification. The Phase 3 results will need to establish the magnitude, consistency and clinical relevance of any treatment effect. The study’s findings will also determine how well changes in these symptoms correspond with broader functional outcomes.

Phase 2 SHIMMER Findings Support Further Evaluation

The planned pivotal study builds on the Phase 2 SHIMMER trial (NCT05225415), which evaluated zervimesine in patients with DLB. Cognition has reported that zervimesine slowed progression across neuropsychiatric, cognitive, motor and functional symptom domains.

In an earlier analysis, the company reported an 89% slowing of progression in hallucinations and delusions compared with placebo, as measured by the Neuropsychiatric Inventory. This result provides a specific clinical rationale for focusing the pivotal study on DLB-associated psychosis.

The finding remains preliminary evidence from a Phase 2 study and should not be interpreted as the expected effect in Phase 3. Confirmation in a larger pivotal trial will be important to establish whether the reported benefit is reproducible and clinically meaningful. Cognition has also reported that zervimesine has generally been well tolerated in clinical studies to date.

Beyond DLB, Phase 2 studies of zervimesine have concluded in mild-to-moderate Alzheimer’s disease and geographic atrophy secondary to dry age-related macular degeneration. The separate Phase 2 START study (NCT05531656) is evaluating zervimesine in early Alzheimer’s disease.

Unmet Need and Development Outlook

DLB is a progressive neurodegenerative disease characterised by cognitive impairment, motor symptoms and neuropsychiatric disturbances. Cognition estimates that approximately 1.4 million Americans live with the condition, although many cases may remain undiagnosed.

There are no approved treatments that slow the progression of DLB or address all its core features. For patients experiencing psychosis, treatment options can be limited by concerns about the safety of conventional antipsychotic medicines, underscoring the need for better-supported therapeutic approaches.

Cognition is now completing the protocol for its planned registrational trial. The October 22 announcement did not specify a new trial initiation date, enrolment target, expected data readout or regulatory submission timeline. The company had previously projected that its registrational programme would begin in mid-2027; that timeline should be confirmed against any subsequent company update.

The key question is whether zervimesine can reproduce its Phase 2 psychosis findings in a pivotal study and demonstrate a meaningful benefit for patients with DLB. FDA alignment establishes a path for further clinical evaluation, but the trial results will determine whether the candidate can support a future application for approval.

Reference

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies, Cognition Therapeutics, 22 October 2026

Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies (COG1201), ClinicalTrials.gov ID NCT05225415

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer’s Disease, ClinicalTrials.gov ID NCT05531656